Global pharma major Lupin Limited on Monday announced the appointment of Claus Jepsen as President, Global Specialty. According to the company’s statement, he brings over three decades of experience in commercial strategy, portfolio management, and launch planning across Europe, Asia, and the United States.
Claus joins Lupin from Takeda Pharmaceuticals, where he led the Global Strategy for Rare Diseases.
Prior to that Claus was at GlaxoSmithKline, where he served in many roles including country head in Asia, and Global franchise management in Immunology, Respiratory and Neurology therapeutic areas.
Claus has launched major brands like Ellipta in the U.S. and led Advair and Seretide success in Europe and U.S.
“We are delighted to welcome Claus to our executive leadership team. His experience in leading specialty strategy, commercial planning and portfolio choices across key markets will enable us to build our Specialty brand business,” Lupin’s CEO, Vinita Gupta said.
